View Financial HealthSimris Group 배당 및 자사주 매입배당 기준 점검 0/6Simris Group 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률-12.8%자사주 매입 수익률총 주주 수익률-12.8%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • 23hSimris Group AB (PUBL), Annual General Meeting, Jun 24, 2026Simris Group AB (PUBL), Annual General Meeting, Jun 24, 2026, at 16:00 W. Europe Standard Time. Location: at the offices of advokatfirman delphi, nordenskioldsgatan 11 a, 211 19, malmo Sweden공시 • Feb 28+ 4 more updatesSimris Group AB (PUBL) to Report Q3, 2026 Results on Nov 11, 2026Simris Group AB (PUBL) announced that they will report Q3, 2026 results on Nov 11, 2026공시 • Jan 20Simris Group AB (publ) Appoints Julian Read as a New Member of the BoardSimris Group AB (publ) at its EGM held on 19 January 2026 resolved to elect Julian Read as a new member of the board. The board now consists of Jonathan Royce, Frank Puccio, Magnus Högström, Hadrien Forterre, Richard Todd and Julian Read. Julian Read, born 1972, is a member of the board of directors and the managing director of Beyond the Border AB. Julian Read was previously the managing director of Simris Group and Doro AB. Julian Read holds a B.Sc. from Warwick University in Biology and Business.공시 • Nov 10Simris Group Announces CEO ChangesThe Board of Directors of Simris Group has appointed Daniel Kubitza as interim CEO, effective 10 November 2025. Daniel Kubitza has over 20 years of experience in corporate financing, commercialization and strategy development in the life sciences and healthcare industry. During Alexis Roberts-McIntosh’s nearly two years as CEO, Simris has made significant progress in refining its focus on the ADC-payload platform, including its lead candidate microcystin (MC)-based compound, SIMRIS-121.공시 • May 29Simris Group AB (Publ) Appoints Richard Todd and Hadrien Forterre as New Members of the BoardSimris Group AB (publ) at its annual general meeting held on 28 May 2025, approved Richard Todd and Hadrien Forterre as new members of the board. Richard Todd holds a Master of Science in Immunology and a Master of Business Administration from Imperial College and the University of Birmingham. Richard currently serves as a Process Development and Digital Training Fellow at the University of Birmingham. Hadrien Forterre holds a Master of Laws from University Paris Nanterre and Duke University, and a Master of Business Administration from Columbia University. Hadrien currently also serves as vice president and general counsel at Pathify.공시 • Apr 28Simris Group AB (PUBL), Annual General Meeting, May 28, 2025Simris Group AB (PUBL), Annual General Meeting, May 28, 2025, at 16:00 W. Europe Standard Time. Location: at advokatfirman delphis, at naordenskioldsdgatan 11 a, malmo Sweden공시 • Feb 26+ 3 more updatesSimris Group AB (PUBL) to Report Q2, 2025 Results on Aug 13, 2025Simris Group AB (PUBL) announced that they will report Q2, 2025 results on Aug 13, 2025Reported Earnings • Nov 14Third quarter 2024 earnings releasedThird quarter 2024 results: Net loss: kr6.39m (loss narrowed 16% from 3Q 2023). Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has fallen by 57% per year, which means it is significantly lagging earnings.공시 • Oct 19Simris Group Announces Board ChangesSimris Group announces that the company's major owner and chairman Steven Schapera has passed away after complications after surgery. Jonathan Royce for now takes over as chairman of the board of Simris Group AB.Reported Earnings • Aug 15Second quarter 2024 earnings releasedSecond quarter 2024 results: Net loss: kr9.42m (loss narrowed 10% from 2Q 2023).공시 • Jun 28Simris Group AB (Publ) Appoints Jonathan Royce as Members of the BoardSimris Group AB (PUBL) at its annual general meeting held on June 28, 2024, approved the appointment of Jonathan Royce as members of the board. Jonathan Royce holds an MSc in Chemical Engineering from Northeastern University and has several years of experience in the life science industry with a particular specialisation in biotechnology. Jonathan Royce has previously been CEO of Bio-Works Technologies AB. Jonathan Royce is considered independent in relation to the Company and its management, as well as in relation to major shareholders in the Company.Board Change • Jun 06Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. Independent Director Robert Quandt was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.공시 • May 29Simris Group AB (publ) Announces Robert Quandt Declines Re-Election as Member of BoardSimris Group AB (publ) at its annual general meeting to be held on 28 June 2024, announced Robert Quandt has declined re-election as member of the board.공시 • May 17+ 2 more updatesSimris Group AB (PUBL) to Report Q3, 2024 Results on Nov 13, 2024Simris Group AB (PUBL) announced that they will report Q3, 2024 results on Nov 13, 2024공시 • May 01Simris Group AB (PUBL), Annual General Meeting, Jun 28, 2024Simris Group AB (PUBL), Annual General Meeting, Jun 28, 2024.공시 • Mar 13Simris Group AB (PUBL) Announces CEO ChangesSimris Group AB has announced the appointment of Dr. Alexis Roberts-McIntosh, a highly experienced pharmaceutical industry executive, to the position of Group CEO. Alexis Roberts-McIntosh replaces current CEO Julian Read, who will be retained as an Advisor for a handover period of 3 months. Julian Read steps back from the Company in order to pursue other opportunities and will ensure a seamless transfer of knowledge to Alexis Roberts-McIntosh during the handover period. Dr. Roberts-McIntosh's appointment is an integral part of the strategic turnaround of the Simris Group's activities, which is underpinned by the shift in focus of the company from the low-margin and highly competitive dietary supplement space to the high-margin ADC payload pharmaceutical space - where the company's product has a sustainable competitive advantage underpinned by its broad patent protection. In the last 22 months considerable work has been done by outgoing CEO, Julian Read, to redefine Simris' corporate objectives, complete the acquisition of Cyano Biotech GmbH (since renamed Simris Biologics), and bring the Group substantially closer to securing its first ADC license agreement with a drug developer. These actions, combined with the funding support received from Simris Chairman Steven Schapera and other strategic shareholders, ensures that Dr. Roberts- McIntosh inherits a company that has a clear strategy, is operating efficiently, and is funded appropriately. Dr. Roberts-McIntosh holds a Ph.D in Medicinal Chemistry. She began her career with GlaxoSmithKline and has since spent the last 27 years transitioning upward through ever-more senior appointments at some of world's most iconic pharmaceutical companies including Pfizer, Johnson & Johnson, Reckitt Benckiser, and Abbott. She is highly entrepreneurial, has an unblemished record of driving innovative products to commercialisation, and has managed complex teams and large P&L's. By any measure, Alexis is an accomplished leader with a proven history of delivering outstanding sales growth with accompanying profitability.New Risk • Feb 29New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr36m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr36m free cash flow). Share price has been highly volatile over the past 3 months (1,530% average daily change). Earnings have declined by 5.6% per year over the past 5 years. Shareholders have been substantially diluted in the past year (93% increase in shares outstanding). Revenue is less than US$1m (kr5.2m revenue, or US$498k). Market cap is less than US$10m (€6.83m market cap, or US$7.40m).Reported Earnings • Nov 09Third quarter 2023 earnings releasedThird quarter 2023 results: Net loss: kr7.57m (loss widened 27% from 3Q 2022).공시 • Nov 01Simris Group AB (PUBL) announced that it has received SEK 2.9295 million in fundingOn October 30, 2023, Simris Group AB (PUBL) closed the transaction. The transaction entails a dilution effect of approximately 3.2 per cent of the number of shares and votes in the company.Recent Insider Transactions • Sep 27Independent Chairman recently bought €541k worth of stockOn the 22nd of September, Steven Schapera bought around 24m shares on-market at roughly €0.023 per share. This transaction increased Steven's direct individual holding by 3x at the time of the trade. This was the largest purchase by an insider in the last 3 months. Steven has been a buyer over the last 12 months, purchasing a net total of €753k worth in shares.New Risk • Sep 15New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 88% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr47m free cash flow). Share price has been highly volatile over the past 3 months (133% average daily change). Earnings have declined by 3.0% per year over the past 5 years. Shareholders have been substantially diluted in the past year (88% increase in shares outstanding). Revenue is less than US$1m (kr1.8m revenue, or US$161k). Market cap is less than US$10m (€7.03m market cap, or US$7.50m).공시 • Aug 03Simris Group AB Confirms New Patent Application from Its Adc-Payload PlatformSimris Group AB confirmed it has submitted a new patent application covering the optimisation of microcystin-based Antibody Drug Conjugate (ADC) payloads with a strongly improved efficacy and safety profile. Simris also confirms that its original method patent for modifying and producing payloads for ADCs, Antibody Antibiotic Conjugates (AACs) and beyond has now been granted in Israel. Simris' technology platform is currently fully patent protected in key markets including Europe, UK, USA, Australia, Japan, and Middle East.Reported Earnings • Jul 26Second quarter 2023 earnings releasedSecond quarter 2023 results: Net loss: kr10.5m (loss widened 106% from 2Q 2022).공시 • May 09+ 2 more updatesSimris Alg AB (publ) to Report Q3, 2023 Results on Nov 08, 2023Simris Alg AB (publ) announced that they will report Q3, 2023 results on Nov 08, 2023Reported Earnings • Apr 20Full year 2022 earnings released: kr0.17 loss per share (vs kr0.36 loss in FY 2021)Full year 2022 results: kr0.17 loss per share (improved from kr0.36 loss in FY 2021). Net loss: kr24.4m (loss narrowed 14% from FY 2021).Reported Earnings • Feb 18Full year 2022 earnings released: kr0.14 loss per share (vs kr0.36 loss in FY 2021)Full year 2022 results: kr0.14 loss per share (improved from kr0.36 loss in FY 2021). Net loss: kr24.4m (loss narrowed 14% from FY 2021).Reported Earnings • Aug 21Second quarter 2022 earnings released: kr0.039 loss per share (vs kr0.092 loss in 2Q 2021)Second quarter 2022 results: kr0.039 loss per share (up from kr0.092 loss in 2Q 2021). Revenue: kr240.0k (down 71% from 2Q 2021). Net loss: kr5.11m (loss narrowed 29% from 2Q 2021).공시 • Aug 17Simris Alg AB (publ) (OM:SIMRIS B) entered into a binding Letter Of Intent to acquire 100% of the shares in Cyano Biotech GmbH.Simris Alg AB (publ) (OM:SIMRIS B) entered into a binding Letter Of Intent to acquire 100% of the shares in Cyano Biotech GmbH on June 12, 2022. The purchase price will include a combination of cash payments, Simris shares and performance related payments. The deal is subject to customary due diligence which is also due complete at a similar time and is due to complete by end of AugustRecent Insider Transactions • May 17Interim Executive Chairman recently bought €98k worth of stockOn the 11th of May, Steven Schapera bought around 3m shares on-market at roughly €0.03 per share. This was the largest purchase by an insider in the last 3 months. Steven has been a buyer over the last 12 months, purchasing a net total of €112k worth in shares.Reported Earnings • Apr 27First quarter 2022 earnings released: kr0.051 loss per share (vs kr0.087 loss in 1Q 2021)First quarter 2022 results: kr0.051 loss per share (up from kr0.087 loss in 1Q 2021). Revenue: kr3.21m (up 430% from 1Q 2021). Net loss: kr4.03m (loss narrowed 41% from 1Q 2021).Board Change • Apr 27No independent directorsThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 10 experienced directors. No highly experienced directors. No independent directors (11 non-independent directors). Director Adam Springfeldt was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Reported Earnings • Apr 23First quarter 2022 earnings releasedFirst quarter 2022 results: Revenue: kr3.21m (up 431% from 1Q 2021). Net loss: kr4.03m (loss narrowed 41% from 1Q 2021).공시 • Apr 23+ 4 more updatesSimris Alg AB (Publ) Appoints Julian Read as Chief Executive Officer, Effective on May 16, 2022Simris Alg AB (publ) appointed Julian Read as CEO starting May 16, 2022. Julian was most recently Managing Director (Nordics) for Dyson, and before that marketing director (Nordics) for Omega Pharma.Reported Earnings • Feb 17Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: kr0.36 loss per share (down from kr0.35 loss in FY 2020). Revenue: kr6.76m (up 196% from FY 2020). Net loss: kr28.4m (loss widened 11% from FY 2020). Revenue was in line with analyst estimates.Reported Earnings • Nov 15Third quarter 2021 earnings releasedThe company reported a decent third quarter result with improved revenues, although losses increased and control over costs was weaker. Third quarter 2021 results: Revenue: kr2.22m (up 102% from 3Q 2020). Net loss: kr10.7m (loss widened 108% from 3Q 2020).Executive Departure • Sep 23Chief Executive Officer Fredrika Gullfot has left the companyDuring their tenure, earnings grew by 20% annually compared to the industry average of 14%. Fredrika still personally held 1.28m shares (€114k worth) as of June 2021. This is 1.6% of the company. Fredrika is the only executive to leave the company over the last 12 months.Reported Earnings • Aug 21Second quarter 2021 earnings releasedThe company reported a solid second quarter result with improved revenues and control over costs, although losses increased. Second quarter 2021 results: Revenue: kr819.0k (up 220% from 2Q 2020). Net loss: kr7.22m (loss widened 18% from 2Q 2020).Reported Earnings • Apr 21Full year 2020 earnings released: kr0.60 loss per share (vs kr2.29 loss in FY 2019)Full year 2020 results: Net loss: kr25.6m (loss narrowed 4.9% from FY 2019).공시 • Aug 16Simris Alg AB (publ) to Report Q2, 2020 Results on Aug 18, 2020Simris Alg AB (publ) announced that they will report Q2, 2020 results at 8:00 AM, Central European Standard Time on Aug 18, 2020지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 5LU 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: 5LU 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Simris Group 배당 수익률 vs 시장5LU의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (5LU)n/a시장 하위 25% (DE)1.5%시장 상위 25% (DE)4.5%업계 평균 (Personal Products)2.6%분석가 예측 (5LU) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 5LU 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 5LU 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 5LU 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: 5LU 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YDE 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/22 09:07종가2026/05/22 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Simris Group AB (PUBL)는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • 23hSimris Group AB (PUBL), Annual General Meeting, Jun 24, 2026Simris Group AB (PUBL), Annual General Meeting, Jun 24, 2026, at 16:00 W. Europe Standard Time. Location: at the offices of advokatfirman delphi, nordenskioldsgatan 11 a, 211 19, malmo Sweden
공시 • Feb 28+ 4 more updatesSimris Group AB (PUBL) to Report Q3, 2026 Results on Nov 11, 2026Simris Group AB (PUBL) announced that they will report Q3, 2026 results on Nov 11, 2026
공시 • Jan 20Simris Group AB (publ) Appoints Julian Read as a New Member of the BoardSimris Group AB (publ) at its EGM held on 19 January 2026 resolved to elect Julian Read as a new member of the board. The board now consists of Jonathan Royce, Frank Puccio, Magnus Högström, Hadrien Forterre, Richard Todd and Julian Read. Julian Read, born 1972, is a member of the board of directors and the managing director of Beyond the Border AB. Julian Read was previously the managing director of Simris Group and Doro AB. Julian Read holds a B.Sc. from Warwick University in Biology and Business.
공시 • Nov 10Simris Group Announces CEO ChangesThe Board of Directors of Simris Group has appointed Daniel Kubitza as interim CEO, effective 10 November 2025. Daniel Kubitza has over 20 years of experience in corporate financing, commercialization and strategy development in the life sciences and healthcare industry. During Alexis Roberts-McIntosh’s nearly two years as CEO, Simris has made significant progress in refining its focus on the ADC-payload platform, including its lead candidate microcystin (MC)-based compound, SIMRIS-121.
공시 • May 29Simris Group AB (Publ) Appoints Richard Todd and Hadrien Forterre as New Members of the BoardSimris Group AB (publ) at its annual general meeting held on 28 May 2025, approved Richard Todd and Hadrien Forterre as new members of the board. Richard Todd holds a Master of Science in Immunology and a Master of Business Administration from Imperial College and the University of Birmingham. Richard currently serves as a Process Development and Digital Training Fellow at the University of Birmingham. Hadrien Forterre holds a Master of Laws from University Paris Nanterre and Duke University, and a Master of Business Administration from Columbia University. Hadrien currently also serves as vice president and general counsel at Pathify.
공시 • Apr 28Simris Group AB (PUBL), Annual General Meeting, May 28, 2025Simris Group AB (PUBL), Annual General Meeting, May 28, 2025, at 16:00 W. Europe Standard Time. Location: at advokatfirman delphis, at naordenskioldsdgatan 11 a, malmo Sweden
공시 • Feb 26+ 3 more updatesSimris Group AB (PUBL) to Report Q2, 2025 Results on Aug 13, 2025Simris Group AB (PUBL) announced that they will report Q2, 2025 results on Aug 13, 2025
Reported Earnings • Nov 14Third quarter 2024 earnings releasedThird quarter 2024 results: Net loss: kr6.39m (loss narrowed 16% from 3Q 2023). Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has fallen by 57% per year, which means it is significantly lagging earnings.
공시 • Oct 19Simris Group Announces Board ChangesSimris Group announces that the company's major owner and chairman Steven Schapera has passed away after complications after surgery. Jonathan Royce for now takes over as chairman of the board of Simris Group AB.
Reported Earnings • Aug 15Second quarter 2024 earnings releasedSecond quarter 2024 results: Net loss: kr9.42m (loss narrowed 10% from 2Q 2023).
공시 • Jun 28Simris Group AB (Publ) Appoints Jonathan Royce as Members of the BoardSimris Group AB (PUBL) at its annual general meeting held on June 28, 2024, approved the appointment of Jonathan Royce as members of the board. Jonathan Royce holds an MSc in Chemical Engineering from Northeastern University and has several years of experience in the life science industry with a particular specialisation in biotechnology. Jonathan Royce has previously been CEO of Bio-Works Technologies AB. Jonathan Royce is considered independent in relation to the Company and its management, as well as in relation to major shareholders in the Company.
Board Change • Jun 06Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. Independent Director Robert Quandt was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
공시 • May 29Simris Group AB (publ) Announces Robert Quandt Declines Re-Election as Member of BoardSimris Group AB (publ) at its annual general meeting to be held on 28 June 2024, announced Robert Quandt has declined re-election as member of the board.
공시 • May 17+ 2 more updatesSimris Group AB (PUBL) to Report Q3, 2024 Results on Nov 13, 2024Simris Group AB (PUBL) announced that they will report Q3, 2024 results on Nov 13, 2024
공시 • May 01Simris Group AB (PUBL), Annual General Meeting, Jun 28, 2024Simris Group AB (PUBL), Annual General Meeting, Jun 28, 2024.
공시 • Mar 13Simris Group AB (PUBL) Announces CEO ChangesSimris Group AB has announced the appointment of Dr. Alexis Roberts-McIntosh, a highly experienced pharmaceutical industry executive, to the position of Group CEO. Alexis Roberts-McIntosh replaces current CEO Julian Read, who will be retained as an Advisor for a handover period of 3 months. Julian Read steps back from the Company in order to pursue other opportunities and will ensure a seamless transfer of knowledge to Alexis Roberts-McIntosh during the handover period. Dr. Roberts-McIntosh's appointment is an integral part of the strategic turnaround of the Simris Group's activities, which is underpinned by the shift in focus of the company from the low-margin and highly competitive dietary supplement space to the high-margin ADC payload pharmaceutical space - where the company's product has a sustainable competitive advantage underpinned by its broad patent protection. In the last 22 months considerable work has been done by outgoing CEO, Julian Read, to redefine Simris' corporate objectives, complete the acquisition of Cyano Biotech GmbH (since renamed Simris Biologics), and bring the Group substantially closer to securing its first ADC license agreement with a drug developer. These actions, combined with the funding support received from Simris Chairman Steven Schapera and other strategic shareholders, ensures that Dr. Roberts- McIntosh inherits a company that has a clear strategy, is operating efficiently, and is funded appropriately. Dr. Roberts-McIntosh holds a Ph.D in Medicinal Chemistry. She began her career with GlaxoSmithKline and has since spent the last 27 years transitioning upward through ever-more senior appointments at some of world's most iconic pharmaceutical companies including Pfizer, Johnson & Johnson, Reckitt Benckiser, and Abbott. She is highly entrepreneurial, has an unblemished record of driving innovative products to commercialisation, and has managed complex teams and large P&L's. By any measure, Alexis is an accomplished leader with a proven history of delivering outstanding sales growth with accompanying profitability.
New Risk • Feb 29New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr36m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr36m free cash flow). Share price has been highly volatile over the past 3 months (1,530% average daily change). Earnings have declined by 5.6% per year over the past 5 years. Shareholders have been substantially diluted in the past year (93% increase in shares outstanding). Revenue is less than US$1m (kr5.2m revenue, or US$498k). Market cap is less than US$10m (€6.83m market cap, or US$7.40m).
Reported Earnings • Nov 09Third quarter 2023 earnings releasedThird quarter 2023 results: Net loss: kr7.57m (loss widened 27% from 3Q 2022).
공시 • Nov 01Simris Group AB (PUBL) announced that it has received SEK 2.9295 million in fundingOn October 30, 2023, Simris Group AB (PUBL) closed the transaction. The transaction entails a dilution effect of approximately 3.2 per cent of the number of shares and votes in the company.
Recent Insider Transactions • Sep 27Independent Chairman recently bought €541k worth of stockOn the 22nd of September, Steven Schapera bought around 24m shares on-market at roughly €0.023 per share. This transaction increased Steven's direct individual holding by 3x at the time of the trade. This was the largest purchase by an insider in the last 3 months. Steven has been a buyer over the last 12 months, purchasing a net total of €753k worth in shares.
New Risk • Sep 15New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 88% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr47m free cash flow). Share price has been highly volatile over the past 3 months (133% average daily change). Earnings have declined by 3.0% per year over the past 5 years. Shareholders have been substantially diluted in the past year (88% increase in shares outstanding). Revenue is less than US$1m (kr1.8m revenue, or US$161k). Market cap is less than US$10m (€7.03m market cap, or US$7.50m).
공시 • Aug 03Simris Group AB Confirms New Patent Application from Its Adc-Payload PlatformSimris Group AB confirmed it has submitted a new patent application covering the optimisation of microcystin-based Antibody Drug Conjugate (ADC) payloads with a strongly improved efficacy and safety profile. Simris also confirms that its original method patent for modifying and producing payloads for ADCs, Antibody Antibiotic Conjugates (AACs) and beyond has now been granted in Israel. Simris' technology platform is currently fully patent protected in key markets including Europe, UK, USA, Australia, Japan, and Middle East.
Reported Earnings • Jul 26Second quarter 2023 earnings releasedSecond quarter 2023 results: Net loss: kr10.5m (loss widened 106% from 2Q 2022).
공시 • May 09+ 2 more updatesSimris Alg AB (publ) to Report Q3, 2023 Results on Nov 08, 2023Simris Alg AB (publ) announced that they will report Q3, 2023 results on Nov 08, 2023
Reported Earnings • Apr 20Full year 2022 earnings released: kr0.17 loss per share (vs kr0.36 loss in FY 2021)Full year 2022 results: kr0.17 loss per share (improved from kr0.36 loss in FY 2021). Net loss: kr24.4m (loss narrowed 14% from FY 2021).
Reported Earnings • Feb 18Full year 2022 earnings released: kr0.14 loss per share (vs kr0.36 loss in FY 2021)Full year 2022 results: kr0.14 loss per share (improved from kr0.36 loss in FY 2021). Net loss: kr24.4m (loss narrowed 14% from FY 2021).
Reported Earnings • Aug 21Second quarter 2022 earnings released: kr0.039 loss per share (vs kr0.092 loss in 2Q 2021)Second quarter 2022 results: kr0.039 loss per share (up from kr0.092 loss in 2Q 2021). Revenue: kr240.0k (down 71% from 2Q 2021). Net loss: kr5.11m (loss narrowed 29% from 2Q 2021).
공시 • Aug 17Simris Alg AB (publ) (OM:SIMRIS B) entered into a binding Letter Of Intent to acquire 100% of the shares in Cyano Biotech GmbH.Simris Alg AB (publ) (OM:SIMRIS B) entered into a binding Letter Of Intent to acquire 100% of the shares in Cyano Biotech GmbH on June 12, 2022. The purchase price will include a combination of cash payments, Simris shares and performance related payments. The deal is subject to customary due diligence which is also due complete at a similar time and is due to complete by end of August
Recent Insider Transactions • May 17Interim Executive Chairman recently bought €98k worth of stockOn the 11th of May, Steven Schapera bought around 3m shares on-market at roughly €0.03 per share. This was the largest purchase by an insider in the last 3 months. Steven has been a buyer over the last 12 months, purchasing a net total of €112k worth in shares.
Reported Earnings • Apr 27First quarter 2022 earnings released: kr0.051 loss per share (vs kr0.087 loss in 1Q 2021)First quarter 2022 results: kr0.051 loss per share (up from kr0.087 loss in 1Q 2021). Revenue: kr3.21m (up 430% from 1Q 2021). Net loss: kr4.03m (loss narrowed 41% from 1Q 2021).
Board Change • Apr 27No independent directorsThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 10 experienced directors. No highly experienced directors. No independent directors (11 non-independent directors). Director Adam Springfeldt was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Reported Earnings • Apr 23First quarter 2022 earnings releasedFirst quarter 2022 results: Revenue: kr3.21m (up 431% from 1Q 2021). Net loss: kr4.03m (loss narrowed 41% from 1Q 2021).
공시 • Apr 23+ 4 more updatesSimris Alg AB (Publ) Appoints Julian Read as Chief Executive Officer, Effective on May 16, 2022Simris Alg AB (publ) appointed Julian Read as CEO starting May 16, 2022. Julian was most recently Managing Director (Nordics) for Dyson, and before that marketing director (Nordics) for Omega Pharma.
Reported Earnings • Feb 17Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: kr0.36 loss per share (down from kr0.35 loss in FY 2020). Revenue: kr6.76m (up 196% from FY 2020). Net loss: kr28.4m (loss widened 11% from FY 2020). Revenue was in line with analyst estimates.
Reported Earnings • Nov 15Third quarter 2021 earnings releasedThe company reported a decent third quarter result with improved revenues, although losses increased and control over costs was weaker. Third quarter 2021 results: Revenue: kr2.22m (up 102% from 3Q 2020). Net loss: kr10.7m (loss widened 108% from 3Q 2020).
Executive Departure • Sep 23Chief Executive Officer Fredrika Gullfot has left the companyDuring their tenure, earnings grew by 20% annually compared to the industry average of 14%. Fredrika still personally held 1.28m shares (€114k worth) as of June 2021. This is 1.6% of the company. Fredrika is the only executive to leave the company over the last 12 months.
Reported Earnings • Aug 21Second quarter 2021 earnings releasedThe company reported a solid second quarter result with improved revenues and control over costs, although losses increased. Second quarter 2021 results: Revenue: kr819.0k (up 220% from 2Q 2020). Net loss: kr7.22m (loss widened 18% from 2Q 2020).
Reported Earnings • Apr 21Full year 2020 earnings released: kr0.60 loss per share (vs kr2.29 loss in FY 2019)Full year 2020 results: Net loss: kr25.6m (loss narrowed 4.9% from FY 2019).
공시 • Aug 16Simris Alg AB (publ) to Report Q2, 2020 Results on Aug 18, 2020Simris Alg AB (publ) announced that they will report Q2, 2020 results at 8:00 AM, Central European Standard Time on Aug 18, 2020